Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 6 - Massive blood transfusion in trauma care

from Section 1 - Initial management of the trauma patient

References

1. Riskin DJ, Tsai TC, Riskin L, et al. Massive transfusion protocols: the role of aggressive resuscitation versus product ratio in mortality reduction. J Am Coll Surg 2009; 209: 198–205.
2. Nunez TC, Voskresensky IV, Dossett LA, et al. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? J Trauma Acute Care Surg 2009; 66: 346–52.
3. Hoyt DB, Dutton RP, Hauser CJ, et al. Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice. J Trauma Acute Care Surg 2008; 65: 755–64.
4. Hess JR, Holcomb JB, Hoyt DB. Damage control resuscitation: the need for specific blood products to treat the coagulopathy of trauma. Transfusion 2006; 46: 685–6.
5. Gunter OL, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma Acute Care Surg 2008; 65: 527–34.
6. Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR. Blood transfusion rates in the care of acute trauma. Transfusion 2004; 44: 809–13.
7. Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma Acute Care Surg 2006; 60 (6 Suppl): S91–6.
8. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma Acute Care Surg 2007; 63: 805–13.
9. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248: 447–58.
10. Snyder CW, Weinberg JA, McGwin G, et al. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma Acute Care Surg 2009; 66: 358–62.
11. Magnotti LJ, Zarzaur BL, Fischer PE, et al. Improved survival after hemostatic resuscitation: does the emperor have no clothes? J Trauma Acute Care Surg 2011; 70: 97–102.
12. Davenport R, Curry N, Manson J, et al. Hemostatic effects of fresh frozen plasma may be maximal at red cell ratios of 1: 2. J Trauma Acute Care Surg 2011; 70: 90–5.
13. de Biasi AR, Stansbury LG, Dutton RP, et al. Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma. Transfusion 2011; 51: 1925–32.
14. Ho AM, Dion PW, Yeung JH, et al. Prevalence of survivor bias in observational studies on fresh frozen plasma: erythrocyte ratios in trauma requiring massive transfusion. Anesthesiology 2012; 116: 716–28.
15. Sihler KC, Napolitano LM. Complications of massive transfusion. Chest 2010; 137: 209–20.
16. Dunne JR, Malone DL, Tracy JK, Napolitano LM. Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. Surg Infect (Larchmt) 2004; 5: 395–404.
17. Asehnoune K, Roquilly A, Abraham E. Innate immune dysfunction in trauma patients: from pathophysiology to treatment. Anesthesiology 2012; 117: 411–16.
18. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104–7.
19. Murphy TJ, Paterson HM, Mannick JA, Lederer JA. Injury, sepsis, and the regulation of Toll-like receptor responses. J Leukoc Biol 2004; 75: 400–7.
20. Marik PE, Flemmer M. The immune response to surgery and trauma: Implications for treatment. J Trauma Acute Care Surg 2012; 73: 801–8.
21. Adib-Conquy M, Asehnoune K, Moine P, Cavaillon JM. Long-term-impaired expression of nuclear factor-kappa B and I kappa B alpha in peripheral blood mononuclear cells of trauma patients. J Leukoc Biol 2001; 70: 30–8.
22. Kim JY, Park JS, Strassheim D, et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol 2005; 288: L958–65.
23. Plurad DS, Talving P, Lam L, et al. Early vasopressor use in critical injury is associated with mortality independent from volume status. J Trauma Acute Care Surg 2011; 71: 565–70.
24. Sperry JL, Minei JP, Frankel HL, et al. Early use of vasopressors after injury: caution before constriction. J Trauma Acute Care Surg 2008; 64: 9–14.
25. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23–32.
26. CRASH-2 Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial. BMJ 2011; 343: d3795.
27. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 2012; 147: 113–19.
28. Goobie SM, Meier PM, Pereira LM, et al. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology 2011; 114: 862–71.
29. Dadure C, Sauter M, Bringuier S, et al. Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study. Anesthesiology 2011; 114: 856–61.
30. Raab H, Lindner KH, Wenzel V. Preventing cardiac arrest during hemorrhagic shock with vasopressin. Crit Care Med 2008; 36 (11 Suppl): S474–80.
31. Robin JK, Oliver JA, Landry DW. Vasopressin deficiency in the syndrome of irreversible shock. J Trauma Acute Care Surg 2003; 54 (5 Suppl): S149–54.
32. Krismer AC, Dunser MW, Lindner KH, et al. Vasopressin during cardiopulmonary resuscitation and different shock states: a review of the literature. Am J Cardiovasc Drugs 2006; 6: 51–68.
33. Raedler C, Voelckel WG, Wenzel V, et al. Treatment of uncontrolled hemorrhagic shock after liver trauma: fatal effects of fluid resuscitation versus improved outcome after vasopressin. Anesth Analg 2004; 98: 1759–66.
34. Voelckel WG, Raedler C, Wenzel V, et al. Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med 2003; 31: 1160–5.
35. Morales D, Madigan J, Cullinane S, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999; 100: 226–9.
36. Krismer AC, Wenzel V, Voelckel WG, et al. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock. Three cases and a brief analysis of the literature. Anaesthesist 2005; 54: 220–4.
37. Sharma RM, Setlur R. Vasopressin in hemorrhagic shock. Anesth Analg 2005; 101: 833–4.
38. Tsuneyoshi I, Onomoto M, Yonetani A, Kanmura Y. Low-dose vasopressin infusion in patients with severe vasodilatory hypotension after prolonged hemorrhage during general anesthesia. J Anesth 2005; 19: 170–3.
39. Lienhart HG, Wenzel V, Braun J, et al. [Vasopressin for therapy of persistent traumatic hemorrhagic shock: The VITRIS.at study]. Anaesthesist 2007; 56: 145–8.
40. Lienhart HG, Lindner KH, Wenzel V. Developing alternative strategies for the treatment of traumatic haemorrhagic shock. Curr Opin Crit Care 2008; 14: 247–53.
41. Al Douri M, Shafi T, Al Khudairi D, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S121–7.
42. Ponschab M, Landoni G, Biondi-Zoccai G, et al. Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2011; 25: 804–10.
43. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201–5.
44. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777–85.
45. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003; 53: 34–8.
46. Knudson MM, Cohen MJ, Reidy R, et al. Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg 2011; 212: 87–95.
47. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma Acute Care Surg 2004; 57: 709–18; discussion 18–19.
48. Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma Acute Care Surg 2008; 64: 286–93.
49. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma Acute Care Surg 2005; 59: 8–15.
50. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital.J Trauma Acute Care Surg 2008; 64 (2 Suppl): S79–85.
51. Fries D, Haas T, Klingler A, et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy–a porcine model. Br J Anaesth 2006; 97: 460–7.
52. Fries D. The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. Transfusion 2013; 53 (Suppl 1): 91S–5S.
53. Mitterlechner T, Innerhofer P, Streif W, et al. Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model. J Thromb Haemost 2011; 9: 729–37.
54. Bickell WH, Wall MJ, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994; 331: 1105–9.
55. Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma Acute Care Surg 2002; 52: 1141–6.
56. Juern J, Khatri V, Weigelt J. Base excess: a review. J Trauma Acute Care Surg 2012; 73: 27–32.
57. Davis JW, Parks SN, Kaups KL, Gladen HE, O’Donnell-Nicol S. Admission base deficit predicts transfusion requirements and risk of complications. J Trauma Acute Care Surg 1996; 41: 769–74.
58. Davis JW, Kaups KL, Parks SN. Base deficit is superior to pH in evaluating clearance of acidosis after traumatic shock. J Trauma 1998; 44: 114–18.
59. Regnier MA, Raux M, Le Manach Y, Asencio Y, Gaillard J, Devilliers C, et al. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology 2012; 117: 1276–88.
60. Cotton BA, Faz G, Hatch QM, et al. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma Acute Care Surg 2011; 71: 407–14.
61. Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256: 476–86.
62. Sankarankutty A, Nascimento B, Teodoro da Luz L, Rizoli S. TEG(R) and ROTEM(R) in trauma: similar test but different results? World J Emerg Surg 2012; 7 (Suppl 1): S3.